Cannabinoid ligands and their effects on learning and performance in rhesus monkeys

Behavioural Pharmacology

Volumn 10, Issue 5, 1999, Pages 497-511

  Winsauer, Peter J ^a   Lambert, P ^a   Moerschbaecher, J M ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

Cannabidiol; Learning; Monkey; Repeated acquistion; SR141716A; WIN 55,212 2; 9 tetrahydrocannabinol

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABIDIOL; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DRONABINOL; RIMONABANT;

ACCURACY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISCRIMINATION LEARNING; DOSE RESPONSE; FEMALE; LEARNING; MALE; NONHUMAN; RHESUS MONKEY; TASK PERFORMANCE;

EID: 0032860394     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-199909000-00008     Document Type: Article

References (44)

1. Aigner TG (1988). Delta-9-tetrahydrocannabinol impairs visual recognition memory but not discrimination learning in rhesus monkeys. Psychopharmacology (Berl) 95:507-511.
2. Ali SF, Newport GD, Scallet AC, Paule MG, Bailey JR, Slikker WJ (1991). Chronic marijuana smoke exposure in the rhesus monkey. IV: Neurochemical effects and comparison to acute and chronic exposure to delta-9-tetrahydrocannabinol (THC) in rats. Pharmacol Biochem Rehav 40:677-682.
3. Axelrod J, Felder CC (1998). Cannabinoid receptors and their endogenous agonist, anandamide. Neurochem Res 23:575-581.
4. Bickel WK, Hughes JR, Higgins ST (1989). Effects of Delta-9-THC on repeated acquisition and performance of response chains in humans. NIDA Res Monogr 95:440-441.
5. Brady KT, Balster RL (1980). The effects of delta 9-tetrahydrocannabinol alone and in combination with cannabidiol on fixed-interval performance in rhesus monkeys. Psychopharmacology (Berl) 72:21-26.
6. Branch MN, Dearing ME, Lee DM (1980). Acute and chronic effects of delta 9-tetrahydrocannabinol on complex behavior of squirrel monkeys. Psychopharmacology (Berl) 71:247-256.
7. Brodkin J, Moerschbaecher JM (1997). SR141716A antagonizes the disruptive effects of cannabinoid ligands on learning in rats. J Pharmacol Exp Ther 282:1526-1532.
8. Christensen HD, Freudenthal RI, Gidley JT et al. (1971). Activity of delta8-and delta9-tetrahydrocannabinol and related compounds in the mouse. Science 172:165-167.
9. Compton DR, Aceto MD, Lowe J, Martin BR (1996). In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277:586-594.
10. Coutts AA, Pertwee RG (1997). Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br J Pharmacol 121:1557-1566.
11. Evans EB, Wenger GR (1992). Effects of drugs of abuse on acquisition of behavioral chains in squirrel monkeys. Psychopharmacology (Berl) 107:55-60.
12. Foltin RW, Brady JV, Fischman MW (1986). Behavioral analysis of marijuana effects on food intake in humans. Pharmacol Biochem Behav 25:577-582.
13. Gessa CL, Mascia MS, Casu MA, Carta G (1997). Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A. Eur J Pharmacol 327:R1-R21.
14. Gifford AN, Ashby CRJ (1996). Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. J Pharmacol Exp Ther 277:1431-1436.
15. Gluck JP, Ferraro DP, Marriott RG (1973). Retardation of discrimination reversal by delta9-tetrahydrocannabinol in monkeys. Pharmacol Biochem Behav 1:605-608.
16. Guimaraes FS, De AJ, Mechoulam R, Breuer A (1994). Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. Gen Pharmacol 25:161-164.
17. Herkenham M, Lynn AB, Little MD et al. (1990). Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932-1936.
18. Heyser CJ, Hampson RE, Deadwyler SA (1993). Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J Pharmacol Exp Ther 264:294-307.
19. Hudzik TJ, McMillan DE (1994). Drug effects on response duration differentiation. I: Differential effects of drugs of abuse. Psychopharmacology (Berl) 114:620-627.
20. Kelly TH, Foltin RW, Emurian CS, Fischman MW (1993). Performance-based testing for drugs of abuse: Dose and time profiles of marijuana, amphetamine, alcohol and diazepam. J Anal Toxicol 17:264-272.
21. Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI (1997). SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 334:R1-R2.
22. Lichtman AH, Martin BR (1996). Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology (Berl) 126:125-131.
23. Lichtman AH, Dimen KR, Martin BR (1995). Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology (Berl) 119:282-290.
24. MacLennan SJ, Reynen PH, Kwan J, Bonhaus DW (1998). Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br J Pharmacol 124:619-622.
25. Mallet PE, Beninger RJ (1996). Delta9-tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance. Life Sci 62:2431-2439.
26. Mansbach RS, Rovetti CC, Winston EN, Lowe JA (1996). Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacology (Berl) 124:315-322.
27. Moerschbaecher JM, Thompson DM (1983). Differential effects of prototype opioid agonists on the acquisition of conditional discriminations in monkeys. J Pharmacol Exp Ther 226:738-748.
28. Moerschbaecher JM, Devia C, Brocklehurst C (1987). Effects of mixed agonist-antagonist opioids on the acquisition of conditional discriminations in monkeys. J Pharmacol Exp Ther 240:74-81.
29. Nakamura EM, Da SE, Concilio GV, Wilkinson DA, Masur J (1991). Reversible effects of acute and long-term administration of delta-9-tetrahydrocannabinol (THC) on memory in the rat. Drug Alcohol Depend 28:167-175.
30. Nakamura-Palacios EM, Winsauer PJ, Moerschbaecher JM (1997). Disruptive effects of delta-9-THC on learning and memory in rats and squirrel monkeys. In: Building International Research in Drug Abuse. National Institute on Drug Abuse (NIDA), Bethesda, MD, p. 44.
31. Onaivi ES, Green MR, Martin BR (1990). Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 253:1002-1009.
32. Pertwee RG (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129-180.
33. Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC (1998). Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63:L1-L6.
34. Reggio PH, Bramblett RD, Yuknavich H et al. (1995). The design, synthesis and testing of desoxy-CBD: further evidence for a region of steric interference at the cannabinoid receptor. Life Sci 56:2025-2032.
35. Richardson JD, Aanonsen L, Hargreaves KM (1997). SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol 319:R3-R4.
36. Rinaldi-Carmona M, Barth F, Heaulme M et al. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
37. Rinaldi-Carmona M, Barth F, Heaulme M et al. (1995). Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56:1941-1947.
38. Sanudo-Pena MC, Tsou K, Delay ER, Hohman AG, Force M, Walker JM (1997). Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci Lett 223:125-128.
39. Schlicker E, Timm J, Zentner J, Gothert M (1997). Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn Schmiedebergs Arch Pharmacol 356:583-589. [Published erratum appears in Naunyn Schmiedebergs Arch Pharmacol 357:357 (1998).]
40. Schulze GE, McMillan DE, Bailey JR et al. (1988). Acute effects of delta-9-tetrahydrocannabinol in rhesus monkeys as measured by performance in a battery of complex operant tests. J Pharmacol Exp Ther 245:178-186.
41. Terranova JP, Storme JJ, Lafon N, Perio A, Rinaldi-Carmona M, Le Fur G, Soubrie P (1996). Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology (Berl) 126:165-172.
42. Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH (1998). Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 285:285-292.
43. Thompson DM, Moerschbaecher JM (1979). An experimental analysis of the effects of d-amphetamine and cocaine on the acquisition and performance of response chains in monkeys. J Exp Anal Behav 32:433-444.
44. 9-tetrahydrocannabinol in rats and rhesus monkeys. J Pharmacol Exp Ther 275:1-6.